2332518
Cooperative Agreement
Overview
Grant Description
Sbir Phase II: Enhancing Performance and Achieving Commercial Readiness for the Pqs1.0 Rapid Phenylalanine Blood Level Monitor -this small business innovation research (SBIR) Phase II project addresses a pressing need for a rapid and user-friendly method to monitor blood phenylalanine levels in individuals with phenylketonuria (PKU), a lifelong genetic disorder impairing phenylalanine processing, an amino acid found in many common foods.
Left untreated or poorly managed, PKU can result in intellectual disabilities, behavioral issues, and severe health complications. In the U.S., an estimated 20,000 to 35,000 individuals grapple with PKU, demanding consistent blood phenylalanine level monitoring as part of their disease management. The annual costs of PKU care can vary from $15,000 to $200,000 per individual, with higher costs linked to inadequate management, leading to irreversible damage and substantial healthcare services.
Currently, monitoring occurs with intervals of 3 to 5 days or even up to two weeks, constrained by factors like test sites, facility availability, and turnaround times. Ideally, PKU monitoring should align with individual needs, occurring daily in sync with diet, age, health factors, and gestational period. Enhanced monitoring frequency is widely recognized as beneficial, and this project aims to improve PKU care by providing accessible and frequent monitoring for improved patient outcomes.
This small business innovation research (SBIR) Phase II project aims to develop a rapid phenylalanine monitor for phenylketonuria (PKU) patients. The project offers rapid analysis of blood phenylalanine levels to enhance patient outcomes and improve the current standard of care. Consisting of a test strip and a test device, the system accepts a blood drop from a finger prick.
The test strip conditions the blood sample with specific analytes before the test device analyzes the sample. The project's core focus is optimizing product design and system algorithms, enabling cost-effective manufacturing and deployment for end-users. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.- Subawards are not planned for this award.
Left untreated or poorly managed, PKU can result in intellectual disabilities, behavioral issues, and severe health complications. In the U.S., an estimated 20,000 to 35,000 individuals grapple with PKU, demanding consistent blood phenylalanine level monitoring as part of their disease management. The annual costs of PKU care can vary from $15,000 to $200,000 per individual, with higher costs linked to inadequate management, leading to irreversible damage and substantial healthcare services.
Currently, monitoring occurs with intervals of 3 to 5 days or even up to two weeks, constrained by factors like test sites, facility availability, and turnaround times. Ideally, PKU monitoring should align with individual needs, occurring daily in sync with diet, age, health factors, and gestational period. Enhanced monitoring frequency is widely recognized as beneficial, and this project aims to improve PKU care by providing accessible and frequent monitoring for improved patient outcomes.
This small business innovation research (SBIR) Phase II project aims to develop a rapid phenylalanine monitor for phenylketonuria (PKU) patients. The project offers rapid analysis of blood phenylalanine levels to enhance patient outcomes and improve the current standard of care. Consisting of a test strip and a test device, the system accepts a blood drop from a finger prick.
The test strip conditions the blood sample with specific analytes before the test device analyzes the sample. The project's core focus is optimizing product design and system algorithms, enabling cost-effective manufacturing and deployment for end-users. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.- Subawards are not planned for this award.
Awardee
Funding Goals
THE GOAL OF THIS FUNDING OPPORTUNITY, "NSF SMALL BUSINESS INNOVATION RESEARCH PHASE II (SBIR)/ SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAMS PHASE II", IS IDENTIFIED IN THE LINK: HTTPS://WWW.NSF.GOV/PUBLICATIONS/PUB_SUMM.JSP?ODS_KEY=NSF23516
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
Mission Viejo,
California
92691-6111
United States
Geographic Scope
Single Zip Code
Fakhro Louay K was awarded
Cooperative Agreement 2332518
worth $997,142
from National Science Foundation in May 2024 with work to be completed primarily in Mission Viejo California United States.
The grant
has a duration of 2 years and
was awarded through assistance program 47.084 NSF Technology, Innovation, and Partnerships.
The Cooperative Agreement was awarded through grant opportunity NSF Small Business Innovation Research / Small Business Technology Transfer Phase II Programs (SBIR/STTR Phase II).
SBIR Details
Research Type
SBIR Phase II
Title
SBIR Phase II: Enhancing Performance and Achieving Commercial Readiness for the PQS1.0 Rapid Phenylalanine Blood Level Monitor
Abstract
This Small Business Innovation Research (SBIR) Phase II project addresses a pressing need for a rapid and user-friendly method to monitor blood phenylalanine levels in individuals with phenylketonuria (PKU), a lifelong genetic disorder impairing phenylalanine processing, an amino acid found in many common foods. Left untreated or poorly managed, PKU can result in intellectual disabilities, behavioral issues, and severe health complications. In the U.S., an estimated 20,000 to 35,000 individuals grapple with PKU, demanding consistent blood phenylalanine level monitoring as part of their disease management. The annual costs of PKU care can vary from $15,000 to $200,000 per individual, with higher costs linked to inadequate management, leading to irreversible damage and substantial healthcare services. Currently, monitoring occurs with intervals of 3 to 5 days or even up to two weeks, constrained by factors like test sites, facility availability, and turnaround times. Ideally, PKU monitoring should align with individual needs, occurring daily in sync with diet, age, health factors, and gestational period. Enhanced monitoring frequency is widely recognized as beneficial, and this project aims to improve PKU care by providing accessible and frequent monitoring for improved patient outcomes.
This Small Business Innovation Research (SBIR) Phase II project aims to develop a rapid phenylalanine monitor for phenylketonuria (PKU) patients. The project offers rapid analysis of blood phenylalanine levels to enhance patient outcomes and improve the current standard of care. Consisting of a test strip and a test device, the system accepts a blood drop from a finger prick. The test strip conditions the blood sample with specific analytes before the test device analyzes the sample. The project's core focus is optimizing product design and system algorithms, enabling cost-effective manufacturing and deployment for end-users.
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.
Topic Code
BM
Solicitation Number
NSF 23-516
Status
(Ongoing)
Last Modified 5/6/24
Period of Performance
5/1/24
Start Date
4/30/26
End Date
Funding Split
$997.1K
Federal Obligation
$0.0
Non-Federal Obligation
$997.1K
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
2332518
SAI Number
None
Award ID URI
SAI EXEMPT
Awardee Classifications
Small Business
Awarding Office
491503 TRANSLATIONAL IMPACTS
Funding Office
491503 TRANSLATIONAL IMPACTS
Awardee UEI
VYR3MARJVCS8
Awardee CAGE
86L14
Performance District
CA-40
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Modified: 5/6/24